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Abstract
Cancer is a prevalent disease that is responsible for around 10 million deaths a year. Cases and deaths
will continue to rise daily if nothing is done to find the most effective treatment. Mistletoe is an
evergreen, semi-parasitic plant that grows on trees. This plant contains a number of biologically active
compounds that contribute to its anti-cancer properties e.g., lectins. Mistletoe is obtained from nature
and has been shown to be safe, potent, and effective in treating cancer. Herein we review the
biological effects of mistletoe on cancer cells, formulations that can be used in cancer treatment and
discuss the benefits and caveats of such treatments.
Keywords: mistletoe, cancer, therapy, Viscum album, Viscum fraxini

1. Introduction
In Ireland, the average number of ‘registered tumours’ in males and females is estimated to be
just above 43,000 per year between 2017-2019 (National Cancer Registry Ireland, 2019). 55%
of the registered tumours excluding non-invasive and non-melanoma skin cancers require
extensive treatment as they are life-changing invasive cancers (National Cancer Registry
Ireland, 2019). The treatment of cancer differs depending on type. The treatments a cancer
patient can undergo are surgery, radiation therapy, chemotherapy, hormonal therapy, target
therapy and immunotherapy (Miller et al., 2019).
As cancer is a prevalent disease a number of unconventional therapies have been discovered.
One unconventional therapy is the use of mistletoe. Mistletoe is used in primary, adjuvant and
palmitate treatment of cancer (Urech & Baumgartner, 2015). Mistletoe has been used to treat
more than 80,000 patients between medical clinics in Switzerland and Germany since the 1920s
(Kaegi, 1998). Iscador is the name of the mistletoe preparation that is commercially available
in Europe and South Africa (Kaegi, 1998). Cancer patients undergo unconventional therapies
to improve their quality of life (QoL) and to help manage symptoms such as nausea (Vickers
& Cassileth, 2001).

2. Mistletoe
Mistletoe is an evergreen plant and is a semi-parasitic plant that grows on trees e.g., apple, elm,
oak, and pine trees (Kaegi, 1998). Mistletoe is native to many parts of Europe but it rarely
grows in northern and far eastern Europe as mistletoe cannot survive the low temperatures of -
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20oC (Iscador AG, 2018). Mistletoe also has trouble growing in the south of Europe due to the
strong sunlight and aridity (Iscador AG, 2018). White-berried mistletoe (Viscum album L.) is
used in cancer treatment and is split into three botanical subspecies, pine mistletoe (Viscum
album ssp. austriacum), fir mistletoe (Viscum album ssp. abietis) and deciduous mistletoe
(Viscum album ssp. Album) (Becker, 1986). Viscum fraxini is mistletoe that grows on ash trees
(Yang et al, 2019). Viscum album is the European species of mistletoe (Becker, 1986).
Mistletoe species can only grow on specific host trees (Iscador AG, 2018).
Historically the use of mistletoe as a cancer therapy was documented in the early 20th century
by Rudolf Steiner who used a preparation of white-berried mistletoe (Kaegi, 1998). In 1916,
Ita Wegman following indications from Steiner, then developed Iscar, a parenteral, and treated
the first cancer patient in 1917 (Iscador AG., 2018). The preparation was registered as
ISCADOR after further development in 1926 and is now the most frequently used mistletoe
preparation in cancer treatment (Iscador AG., 2018).
Chemical composition of mistletoe
Mistletoe contains a number of different types of biologically active compounds (e.g., lectins,
polysaccharides, viscotoxins, kuttan’s peptides, flavonoids) (see Table 1)(Iscador AG., 2018),
each of which have the potential to interact with cancer cells (Marvibaigi et al., 2014). Plant
lectins interact with cancer cells expressing aberrant glycan structures on their cell surface,
resulting in cell death. Mistletoe contain three structurally similar lectins (ML-I, ML -II and
ML-III) which differ in terms of their ability of carbohydrate binding (Pevzner et al., 2004).
They belong to the type-2 ribosome-inhibiting proteins (RIPs) (Zänker & Kaveri, 2015). These
lectins contain an A chain (which is cytotoxic) and a B chain (carbohydrate binding with
immunomodulatory properties). Binding of the B chain is selective (Marvibaigi et al., 2014).
For example, there are different targets (galactoside alone, galactoside and Nacetylgalactosamine glycans or N-acetylgalactosamine alone) depending on the lectin (MLX)(Majeed et al., 2021). This variation in binding explains the selective cytotoxicity (activation
of intrinsic and extrinsic apoptosis pathways) of lectins on cancer cells (Twardziok et al.,
2016). Viscotoxins contain a phosphate specific binding site and are amphipathic in nature
thereby augmenting their cytotoxicity in cancer cells by altering membrane integrity (Schaller
et al., 1998)(Zänker & Kaveri, 2015). Flavanoid derivatives such as quercetin and quercetin
methyl ester are also found in mistletoe (Pietrzak et al., 2017). These mainly exist in
glycosylated form and induce apoptosis and exhibit scavenger properties. As these components
have different effects in the body and the chemical composition of mistletoe varies depending
on the location and species of host, season and type of harvest, extraction method and
commercial producer (Marvibaigi et al., 2014) we present their distribution in various mistletoe
species (Table 1) and detail their potential anti cancer effect in the remainder of this section.
Mistletoe lectins
Ribosome Inactivating Proteins are highly potent cytotoxins which can interfere with protein
biosynthesis (Beztsinna et al., 2018). These include lectins. The 254 amino acid A-chain
catalyses hydrolysis of the N-glycosidic bond at adenine -4324 in the 28S ribosome, thereby
inhibiting protein elongation and resulting in cell death. The 264 amino acid B-chain binds
carbohydrates which mediates cellular uptake of lectin (Marvibaigi et al., 2014). The B chain
of lectin causes the secretion of cytokines and increases the activity of natural killer (NK) cells
(Marvibaigi et al., 2014).
IL-2 is normally used for activation of NK or T cells isolated from cancer patients (Radulovic
et al., 2003) and is approved by the FDA for the treatment of metastatic renal cell carcinoma
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and metastatic melanoma (Jiang et al., 2016)(Konjevic et al., 2003). However due to its adverse
effects at high dose there is a need to discover natural compounds capable of eliciting a
favourable therapeutic response (Lu & Chen, 2010).
ML-I, ML-II and ML-III can be separated by their molecular weight and their specific sugarbinding characteristics (Urech et al, 2006). The lectin concentration in mistletoe varies
depending on the season and the host tree (Iscador AG., 2018). In winter the mistletoe plant
contains more lectins compared to in the summer (Iscador AG., 2018). In mistletoe that grows
on oak, apple and poplar contain a lot of lectin with ML-I being the predominated one while
mistletoe grown on pine trees have a low lectin concentration with most of the lectin present
being ML-III and containing very little ML-I (Iscador AG., 2018).
Viscotoxins
Viscotoxins are polypeptides with immunogenic effects (Zänker and Kaveri, 2015). They
contain 46 amino acids and three disulphide bridges (Marvibaigi et al., 2014), with a
phosphate-binding site (Zänker & Kaveri, 2015). This binding site can interfere with a cell’s
membrane which destroys it . The cytotoxicity of viscotoxins has been demonstrated in bladder
and breast carcinoma cell lines (Eggenschwiler et al., 2007) .The viscotoxins present in
mistletoe are A1, A2, A3, B, 1-PS and U-PS (Urech et al, 2006). Mistletoe grown on oak trees,
elm trees, apple trees and deciduous trees contain A2 and A3 in high concentrations but do not
contain 1-PS and U-PS (Urech et al, 2006). Mistletoe grown on pine trees contain high levels
of 1-PS and U-PS but does not contain A1 while mistletoe grown on fir trees contain high
levels of A3, a substantial amount of 1-PS and very little A2 (Urech et al, 2006).V. album ssp.
austriacum contains the lowest concentration of viscotoxins compared to other V. album
subspecies (Urech et al, 2006). Different extracts from host trees in abietis and album show no
difference in the viscotoxin concentration (Urech et al, 2006).
Kuttan’s peptides
Kuttan’s peptides are heat resistant peptides with a molecular weight of 5000Da (Kuttan &
Kuttan, 1992). Kuttan’s peptides have been shown to have similar properties to viscotoxins as
they have cytotoxic and immunostimulatory properties (Kuttan & Kuttan, 1992) against tumour
cells (Kuttan & Kuttan, 1993). In vitro and in vivo studies show that kuttan’s peptides stimulate
macrophages and lymphocytes towards the tumour when injected near the tumour site (Kuttan
& Kuttan, 1992). Natural killer cells and antibody dependent cellular cytotoxicity are increased
when administered with these peptides (Kuttan & Kuttan, 1992).
Polysaccharides and oligosaccharides
Polysaccharides and oligosaccharides concentration in mistletoe will change depending on the
season and the part of the plant that is used (Urech & Baumgartner, 2015). Mistletoe berries
contain polysaccharides, examples are rhamnogalacturonans with arabinogalactan side chains,
arabinogalactans, and xyloglucans. Arabinogalactans selectively stimulates the proliferation of
CD4+ T helper lymphocytes, while rhamnogalacturonans stimulate NK cells activity (Urech
& Baumgartner, 2015). The ability of arabinogalactans to induce the intrinsic apoptotic
pathway, increase ROS and decrease cellular proliferation was previously demonstrated in
breast cancer cells (Moghtaderi et al., 2017).
Flavonoids
Flavonoids are present in V. album (Urech & Baumgartner, 2015) with known anti cancer
properties (Kopustinskiene et al., 2020). Its derivatives induce apoptosis in cell culture
models and have antioxidant effects (Iscador AG., 2018).
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Table 1: Constituents present in different types of V. album subspecies.
Constituents
V. album
subspecies
Mistleto

Lectins*

Viscotoxins

Pine album ML-III, ML- A1, A2, A3, B

e species

Kuttan’s

Polysaccharides and

peptides

oligosaccharides

Present

II, ML-I

Flavonoids

Arabinogalactans,

Quercetin

galacturonans

quercetin methyl Baumgartner,
ester

Oak album

ML-I, ML-II, A1, A2, A3, B

Present

ML-III

ML-I, ML-II, A1, A2, A3, B

Present

ML-III

ML-III, ML- A2, A3, B, 1-PS, Present

austriacum II, ML-I

U-PS

&

2015

Quercetin

galacturonans

quercetin methyl Baumgartner,

and Urech

&

2015

Arabinogalactans,

Quercetin

galacturonans

quercetin methyl Baumgartner,
ester

Pine

and Urech

Arabinogalactans,

ester
Elm album

References

and Urech

&

2015

Arabinogalactans,

Quercetin

and Urech et al,

galacturonans

quercetin methyl 2006
ester

Fir abietis

ML-I, ML-II, A1, A3, B, 1-PS
ML-III

Present

Arabinogalactans,

Quercetin

and Urech et al,

galacturonans

quercetin methyl 2006
ester

*ranked from highest concentration to least
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3. Mistletoe and Key Biological Pathways
Mistletoe uses a number of different biological pathways that cause its anti-cancer effects. The
different components (see Table 2) of mistletoe result in different biological effects. These are:
cytotoxicity and apoptosis in tumour cells and inhibition of angiogenesis (Yang et al., 2019).
Cyclooxygenases-2 signalling pathway
Viscum Album preparations influence cyclooxygenases (COX)-2 activity (Oei et al., 2019).
COX-2 is an important enzyme involved in a number of different inflammatory reaction
pathways (Oei et al., 2019). Viscum Album preparations reduce the selectivity of COX-2 in
preclinical studies (lung carcinoma) (Oei et al., 2019). COX-2 upregulation is shown to be
linked with poor colorectal cancer prognosis, and results in an overproduction of prostaglandin
E2 (PGE2) which promotes cell growth, migration, invasion, and survival (Greenhough et al.,
2009). Viscum album preparations can suppress COX-2 activities by posttranscriptional
destabilization of its transcripts (Oei et al., 2019). See Figure 1 for COX-2 pathway.

Figure 1: COX-2 signalling pathway. Arachidonate is released from cell membranes by cytoplasmic
phospholipase A2. Free arachidonic acid is metabolized to eicosanoids. Arachidonic acid is converted
to PGH2 by COX. PGH2 is subsequently metabolised to prostaglandins (PGs) by specific prostaglandin
synthases.

Downregulation of c-Myc expression
Viscum fraxini, an aqueous extract of mistletoe, inhibits the proliferation of liver cancer cells
by the downregulation of c-Myc expression as shown in in vitro (hepatocellular carcinoma)
studies (Yang et al., 2019)(see Figure 2). c-Myc is overexpressed in both viral and alcoholrelated hepatocellular carcinoma and the greater the overexpression of c-Myc, the more
aggressive the form of hepatocellular carcinoma (Yang et al., 2019). This extract increases proapoptotic protein expression e.g., Bax, and inhibits anti-apoptotic protein expression e.g.,
XIAP. It also regulates cell signalling proteins e.g., c-Myc (by its suppression), in a dosedependent manner (Yang et al., 2019). Viscum fraxini affects the translation of c-Myc, not the
transcription as the gene is not altered by its use (Yang et al., 2019).
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Figure 2: Mechanism of V. fraxini interaction with c-Myc pathway. Suppression of c-Myc by V. fraxini
is via a decrease in c-Myc stability which may involve phosphorylation sites T58 and S62 on c-Myc.

MAPK
Mistletoe has been shown to use mitogen-activated protein kinase (MAPK) in in vitro
(leukaemia) studies (Szurpnicka et al., 2020)(see Figure 3). The MAPK pathway used by
mistletoe plays a key role in tumour proliferation (Szurpnicka et al., 2020). MAPKs are
components that are used in signalling pathways to transfer extracellular stimulation into
intracellular responses (Pae et al., 2001). There are three subfamilies of MAPKs which are p44
and p42 MAPKs, p54 and p46 stress-activated protein kinases (SAPK) and p38 MAPK (Pae et
al., 2001). p44 and p42 MAPKs are referred to as extracellular signal-regulated protein kinase
1 and 2 (ERK1/2) as they control cell proliferation and differentiation while protecting cells
from apoptotic cell death (Pae et al., 2001). p38 MAPK and SAPKs are activated by stress
signals e.g., inflammatory cytokines and can promote leukaemia cell death by inhibiting cell
proliferation (Pae et al., 2001). Mistletoe increases p38 MAPK and SAPKs activation and
decreases ERK which leads to apoptosis and cancer cell death (Szurpnicka et al., 2020).
Mistletoe lectin II causes these effects (Pae et al., 2001).

Figure 3: MAPK mechanism of anti-cancer activity of mistletoe. Mistletoe downregulates cyclins
(CCND1, CCNE, CCNA) and cyclin-dependent protein kinases (CDK4, CDK2) inhibiting cell cycle.
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PI3K / AKT
The phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR)
pathway is one of the most important pathways that regulates cell growth, motility, survival,
metabolism and angiogenesis (Katso et al., 2001). Activation of this pathway contributes to the
development of tumours and resistance to anti-cancer therapies (Martini et al., 2014). Mistletoe
targets the signalling pathway phosphatidylinositol 3-kinase (PI3K) (in vitro study in lung
cancer) / protein kinase B (AKT) (in vitro study in submandibular gland squamous cell
carcinoma) which is responsible for the growth and survival of cells (Szurpnicka et al., 2020).
AKT is a target for PI3K as when it is activated it inhibits apoptosis in cells (Choi et al., 2004).
Mistletoe has been shown to downregulates BCL1, BCL2, XIAP which are inhibitors of
apoptosis (IAPs) and upregulates pro-apoptotic proteins (Bax) in in vitro lung cancer studies
(Szurpnicka et al., 2020). Mistletoe activates caspases and releases cytochrome c which leads
to cell apoptosis (Szurpnicka et al., 2020). See Figure 4 for mechanism of action.

Figure 4: PI3K / AKT mechanism of anti-cancer activity of mistletoe. Mistletoe upregulates
proapoptotic proteins (Bax, Bak) and downregulates inhibitors of apoptosis (IAPs) such as BCL2,
BCL2, MCL1, XIAP. Additionally, mistletoe leads to release of cytochrome c and activation of
caspases resulting in apoptosis.
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Table 2: The effect of different mistletoe preparations on cancers.
V. album
preparation

Type of
cancer

Effect

Study type

References

Iscador
Quercus spezial

-------------

Increase of
leukocytes,
granulocytes
and eosinophils

Randomized
clinical trial
(RCT) placebocontrolled trial
on healthy
subjects

Huber et al.,
2005

Viscum album

Breast
cancer

Increase activity
in NK cells

Preclinical study
and clinical trial

Tabiasco et al.,
2002
Hajto, 1986

-------------

Increase p38
MAPK and
SAPKs activity
and decreases
ERK

In vitro

Szurpnicka et al.,
2020
Twardziok et al.,
2017

In vitro

Choi et al., 2004
Park et al., 2012
Klingbeil et al.,
2013
Fan et al., 2019

In vivo

Hegde et al.,
2011

In vivo

Yang et al., 2019

Viscum album
var. coloratum
Iscador M
Viscum album
var. coloratum
Iscador M
Iscador
Quercus spezial
Iscador
Quercus spezial
Viscum fraxini

Lung
cancer,
tongue
cancer,
myeloid
leukaemia
Breast
cancer
Liver
cancer

Downregulation
of IAPs and
upregulation of
Bax
COX-2
signalling
Downregulation
of the c-Myc
expression

4. Mistletoe and the Immune System
Tumours have different pathways that evade the immune system, these pathways include
resistance to immune effector cells, induction of immune tolerance and causing paralysis of
antigen-presenting cells (APCs) e.g., dendritic cells (DCs) (Elluru et al., 2008). DCs stimulate
T cells therefore with tumours suppressing the maturation and activation of DC T-cells are not
attacking the tumour (Elluru et al., 2008). Mistletoe has been shown to stimulate DCs which
in turn stimulates T-cells which can then mount an immune response against the tumour (Elluru
et al., 2008).
Mistletoe increase leukocytes, granulocytes, eosinophils, and lymphocytes, increase the
activity of NK cells and increase cytokine secretion (Szurpnicka et al., 2020) (Huber et al,
2005). NK cells inhibit tumour growth (Hajto, 1986). They kill cancer cells by releasing
cytotoxic substance and inducing apoptosis (Iscador AG., 2018). Granulocytes, neutrophil and
monocytes have been shown to resist tumour growth and metastasis in vivo (Hajto, 1986).
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Lectin (mistletoe constituent) binds to monocytes and macrophages which stimulates the
synthesis and release of cytokines (Iscador AG., 2018).

5. Pharmaceutical Processing
Pharmaceutical processing and the season the mistletoe is harvested influences the
concentration of chemical substituents in the mistletoe extracts (Urech & Baumgartner, 2015).
Extracts of mistletoe from summer and winter have different concentrations of constituents,
therefore to avoid this, the summer and winter extract should be mixed together to avoid
discrepancies (Urech et al., 2006).
Mistletoe formulation
There are a number of different formulations of mistletoe that are used to treat cancer. Iscador
is a fermented aqueous extract of Viscum album and Helixor is an unfermented extract of
Viscum album. These are marketed under different names depending on their mistletoe source:
Iscador M : derived from apple trees; Malus domestica, Iscador P : derived from mistletoe
grown on pine trees; Pinus sylvestris), Iscador Qu (from oak trees; Quercus robur), Iscador U
(from elm trees; Ulmus minor), Iscador A : derived from mistletoe grown on fir trees. Helixor
M is derived from mistletoe grow on apple trees and Viscum fraxini, Helixor P (from pine trees)
and Helixor A (from spruce trees; Picea abies) (Becker, 1986) (Kleijnen & Knipschild, 1994).
Eurixor is a mistletoe formulation that uses unfermented Viscum album from poplar trees
(Kleijnen & Knipschild, 1994).
Mistletoe harvest
Mistletoe harvest takes place twice a year, in summer and in winter, and is separated depending
on the host tree (Iscador AG., 2018). The harvest takes place in summer when mistletoe is at
the peak of its vegetative development and in winter when the berries and fruit are fully
developed (Iscador AG., 2018). This is to ensure that mistletoe ideal physiological stages are
harvested (Urech et al., 2006).
The parts of mistletoe that are harvested are one- to- two year old leaves, stems, buds, and
ripened berries in winter (Iscador AG., 2018). These are then separated from the mistletoe bush
and are taken to the manufacturing site (Iscador AG., 2018).
Preparation of Iscador
The mistletoe parts after sorting are crushed using rolling mills and are then mixed with water
(Iscador AG., 2018). This aqueous extract from a Viscum Album plant is then fermented for
three days (plant) to four days (berries) with Lactobacillus plantarum to make Iscador (Kaegi,
1998) (Iscador AG., 2018). The product is mixed and then filtered to remove Lactobacillus
plantarum and insoluble plant residues (Kaegi, 1998) (Iscador AG., 2018). The summer and
winter extract of the same mistletoe plant are mixed together at a 1:1 ratio (Iscador AG., 2018).
This product is then standardised and packaged for injections (Kaegi, 1998). The only
difference in formulations for Iscador M, Iscador P and Iscador A is the type of mistletoe used
(Kaegi, 1998). See Figure 5.
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Figure 5: Harvest and preparation of Iscador. Mistletoe is harvested, sorted, crushed, fermented, filtered
and packaged for use.

6. Clinical Treatment with Mistletoe Formulations
Mistletoe injections
Mistletoe extractions are administered as injectables as lectins structures are degraded in the
gastrointestinal tract and have poor absorption (Lyu et al, 2004). Iscador is injected into the
tumour or as near as possible to the tumour site by subcutaneous injections into the abdominal
wall (Kaegi, 1998). This treatment usually takes place three to seven times a week over several
weeks but the treatment is adjusted to the patient’s general condition (Kaegi, 1998). Iscador
treatment can be taken alongside chemotherapy and radiotherapy (Kaegi, 1998) (Oei et al,
2019).
Iscador
Viscum Album is thought to reduce tumour size, stimulate an immune response, and improve
wellbeing and may improve survival in patients with breast, lung, liver, stomach, ovary, cervix,
and colon cancer (Kaegi, 1998). Iscador M, Iscador P are used to treat breast, cervix, lung,
stomach, ovary, and colon cancer (Marvibaigi et al., 2014) (Kaegi, 1998). Breast cancer
patients that underwent treatment using Iscador M were found to have a decrease in tumourrelated symptoms and fatigue, and health-related quality of life improved (HRQoL)
(Marvibaigi et al., 2014). Breast cancer patients that underwent treatment using Iscador P were
found to have a decrease in tumour-related symptoms, enhanced self-regulation and survival
time increased (Marvibaigi et al., 2014).
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Helixor
Helixor is a formulation made from Viscum Album (Lee et al., 2018). As stated previously there
are three types of Helixor: Helixor A, Helixor M and Helixor P (Kleijnen & Knipschild, 1994).
Helixor A is used to treat brain tumours, lung, head and neck cancer. (Helixor, 2021) Helixor
M is used to treat bladder and post-menopausal cancer (Helixor, 2021). Helixor P is used to
treat skin, kidney, testicular and pre-menopausal breast cancer (Helixor, 2021). Breast cancer
patients that underwent Helixor A treatment were found to have an improvement in HRQoL
and a decrease in the side effects of chemotherapy (Marvibaigi et al., 2014) (Kienle & Kienle,
2007).
Isorel
Isorel is a formulation made from the entire plant of Viscum Album (Zarkovic et al., 2001).
Isorel is produced by Novipharm GmbH (Zarkovic et al., 2001). Isorel M is made from
mistletoe on a pine tree (Zarkovic et al., 2001). It inhibits the growth of malignant cells,
stimulates the patient’s immune system, and increase the effectiveness of chemotherapy and
radiotherapy (Zarkovic et al., 2001). When Isorel is taken in conjunction with chemotherapy it
is thought to reduce the harmful mutagenic effects of oxygen-free radicals (Zarkovic et al.,
2001). It has been used to treat colorectal cancer (Cazacu et al., 2003).
Lektinol
Lektinol is a formulation made from extracts of Viscum Album (Mengs et al., 2001). Lektinol
is produced by Madaus AG (Mengs et al., 2001). Lektinol has been shown to be cytotoxic to
breast, prostate, lung, and renal cancers in in vitro studies (Mengs et al., 2001).
Fermented versus unfermented mistletoe preparation
The fermentation status of preparations determines the overall effectiveness of their anti-cancer
status. Fermented mistletoe preparation Iscador (used in cancer therapy for decades) and an
unfermented mistletoe preparation of the same were compared to see which preparation of
mistletoe is better for the treatment of cancer (Ribéreau-Gayon et al., 1986). The mistletoe
preparations were tested in two cell lines rat hepatoma tissue culture (HTC) cells and human
leukaemia Molt 4 cells (Ribéreau-Gayon et al., 1986). The concentration of lectins in
unfermented mistletoe preparation is 10 times higher than in fermented mistletoe preparation
which is approximately 100ng/ml (Ribéreau-Gayon et al., 1986). Fermented mistletoe was
more potent than unfermented mistletoe inhibiting cell growth of HTC cells while unfermented
mistletoe has a stronger cytotoxic effect on Molt 4 cells than HTC cells (Ribéreau-Gayon et
al., 1986) .
In general the tolerability of mistletoe extracts (summarised in Table 3) is largely good and in
preclinical trials, there was no toxicity observed at low doses (Kienle et al, 2009). However,
ingestion of the raw plant could cause seizures and in the worst-case death (Kaegi, 1998).
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Table 3: Mistletoe formulation and cancer treatment.
Formulation name

Administration

Cancer

Effect

Reference

Iscador A

Injection

Breast, lung, colon, rectum,
stomach cancer

Increase in HRQoL, increase in
survival time

Kienle & Kienle, 2007

Iscador M

Injection

Breast, cervix, lung, ovary,
stomach, and colon cancer

Iscador P

Injection

Breast, cervix, lung, ovary,
stomach, and colon cancer

Viscum fraxini

Injection

Liver and pancreatic cancer

Helixor A

Injection

Brain tumours, lung, head and neck
cancer

Helixor M

Injection

Bladder and breast cancer (postmenopausal)

Helixor P

Injection

Skin, kidney, testicular and breast
cancer (pre-menopausal)

https://arrow.tudublin.ie/sure_j/vol4/iss1/1

HRQoL improved, symptoms
decreased, and fatigue
decreased
A decrease in symptoms,
enhanced self-regulation and an
increase in survival time
Downregulation of the c-Myc
expression

Marvibaigi et al., 2014

Marvibaigi et al., 2014
Yang et al, 2019

Improved HRQoL and a
decrease in chemotherapy side
effects
Inhibition of epidermal growth
factor which induced the
proliferation of cells

Marvibaigi et al., 2014,
Helixor, 2021,
Kienle & Kienle, 2007

Cytotoxic activity on tumour
cells

Marvibaigi et al., 2014,
Helixor, 2021

Marvibaigi et al., 2014,
Helixor, 2021
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7. Benefits and Caveats of Mistletoe Treatment
Mistletoe as an add-on cancer treatment alongside chemotherapy and/or radiotherapy has a
number of advantages and disadvantages. The patients and medical professional need to access
the advantages and disadvantages and decide if mistletoe treatment is right for them.
Benefits of mistletoe treatment
The advantages of mistletoe treatment are improvement in QoL and survival time for the
patient, reduction in the side effects and adverse drug reactions by chemotherapy and
radiotherapy, increase in the immunological response, inhibition of cancer cell proliferation
and patients that undergo mistletoe treatment have a reduction in hospitalization stay
(Marvibaigi et al., 2014) (Matthes et al, 2010) (Oei et al, 2019) (Kienle et al, 2009) (Yang et
al, 2019).
Caveats of mistletoe treatment
The disadvantages of the use of mistletoe as an add-on treatment for cancer are at the injection
site, where there can be swelling and local pain. Side effects that can occur during mistletoe
treatment are fever, flu-like symptoms, headaches, and chills (Kienle et al, 2009) (Kaegi,
1998). While there are a number of side effects for the use of mistletoe, they are not permanent
and will subside over time and not every patient will experience them (Kienle et al, 2009).

8. Clinical Trials
Current clinical trial on Iscador Qu
As of the time of writing this article there is currently a clinical trial recruiting patients with
primary and recurrent inoperable pancreatic cancer in Stockholm, Sweden (Wode, 2019). This
is a phase three trial. It started in June 2016 and is ongoing as of May 2022. The trial is a
randomized double-blinded multicentre parallel-group placebo-controlled clinical trial (Wode,
2019). The main aims of the clinical trials (see Table 4) are to determine the overall survival
of patients, evaluate the quality of life, weight of patients and to see if the adverse effects of
chemotherapy decrease (Wode, 2019).
Completed phase one clinical trial on Iscucin Populi and Viscum Mali
There are also a number of completed clinical trials for mistletoe as a cancer treatment. The
University medical centre in Freiburg, Germany completed a phase one clinical trial study on
two mistletoe preparations (Iscucin Populi (IP) and Viscum Mali (VM)) (Huber, 2011). The
trial started in January 2008, there were seventy-one healthy participants aged between 18-45
years. The participants involved had no disease except hay fever, did not smoke or abuse drugs
and were not pregnant (Huber, 2011). The trial was a three-armed randomized study (Huber,
2011). There were three different dose strengths of IP and VM, for IP the strengths were called
F, G and H and for VM the dose strengths were called D3, D2 and 2% of each. Each dose of
the mistletoe preparations was given twice a week for four weeks starting with the F for IP and
then working up to H and for VM it started with D3 and working up to 2% of each and the
results that were found were compared to the placebo results (Huber, 2011). The results found
that there was a strong local reaction at the injection site for the IP strength G and H which
caused distinct eosinophilia and there was a significant increase in the total amount of
leucocytes (Huber et al, 2011). T-helper cell counts increased with the use of IP strength F, G
and H compared to the placebo (Huber et al, 2011). There were only mild local reactions for
VM but there was a small but insignificant increase of eosinophils (Huber et al, 2011). The
clinical trial found that the IP strength G and H should only be given after a pre-treatment with
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a low dose first to make them more tolerable (Huber et al, 2011). Both preparations were found
to be safe (Huber et al, 2011). As the trial was only a phase one trial a further trial will be
required on cancer patients to understand the effect of the mistletoe preparations on cancer.
Completed phase two clinical trial on abnoba viscum fraxini
On the 29th of January 2004, Abnoba Gmbh completed a phase two clinical trial on abnoba
viscum fraxini (Ruebben, 2013). The trial was to determine the maximum dose, safety, and
effectiveness of viscum fraxini after transurethral resection of nonmuscle invasive bladder
cancer (Ruebben, 2013). There were thirty-seven participants with aged between 18-80 years
(Ruebben, 2013). One patient was excluded since the patient had not been treated therefore
thirty-six participants underwent the trial, five women and thirty-one men (Rose et al., 2015).
The trial was a single group dose-escalation study (Ruebben, 2013). The dose started at 45mg
of abnoba viscum fraxini 2 and went up to 675mg of abnoba viscum fraxini 2 (Rose et al.,
2015). The participants were split into groups of three and were started at the lowest dose.
(Rose et al., 2015) If no WHO grade III toxicity was observed the next dose level was tested
in another group of three patients (Rose et al., 2015). The study found that there was no doselimiting toxicity up to the administration of 675mg abnoba viscum fraxini 2 because there was
no single grade three toxicity observed (Rose et al., 2015). Some side effects observed were
urinary tract infection and irritations, and pyrexia. (Rose et al., 2015) Before the treatment
began the participants underwent transurethral resection of bladder tumours and a marker
tumour was left (Rose et al., 2015). 55.6% of patients had complete remission of the marker
tumour which showed strong evidence of the efficacy of abnoba viscum fraxini 2 (Rose et al.,
2015). As this was a phase II study further studies are required to confirm the efficacy of this
treatment.
Completed phase four clinical trial on abnoba viscum quercus
In March 2006, Abnoba GmbH completed a phase four clinical trial on Abnoba-viscum
Quercus (Kim, 2011). The trial was to determine the QoL, immunomodulation, and safety of
adjuvant mistletoe treatment in patients with gastric carcinoma (stage Ib/II) receiving
chemotherapy after operation (Kim, 2011). The study took place at the ASAN medical centre
Seoul, Republic of Korea. There were thirty-two participants with an aged 19-70 years. The
study was prospective, controlled, and randomized, comparing two arms. The patients were
randomly allocated to the intervention group or the control group (no additional therapy),
sixteen in each (Kim et al., 2012). Three participants dropped out, one from the intervention
group and two from the control group (Kim et al., 2012). There were no significant differences
in age, sex, height, weight, blood pressure, pulse rate, type of operation (total gastrectomy or
distal gastrectomy) and pathologic classifications between the two cohorts. The number of male
patients was significantly higher in both cohorts. There were 28 patients in stage Ib and one
patient in stage II.
The intervention group underwent oral chemotherapy and mistletoe injection while the control
group only underwent oral chemotherapy (Kim et al., 2012). Abnoba- viscum Quercus was
injected subcutaneously three times a week with an increasing injection dose after a week (Kim
et al., 2012). The dose started at 0.02mg eventually building to 20mg which continued till the
end of the study (Kim et al., 2012). The trial found that there was an increase in the QoL of the
patients who were in the intervention group and the patients’ global health status increased
(Kim et al., 2012). Aside from 3 QoL parameters (pain, eating restrictions, hair loss) and
basophiles baseline of QoL, immunological parameters, hematology and liver function tests
were not different between the groups. White blood cells count, and eosinophils increased in
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the treatment group compared to the control group (Kim et al., 2012). The rate of diarrhoea
decreased in the treatment group compared to the control (Kim et al., 2012).

Table 4: Summary of clinical trials

Mistletoe

Clinical trial

Goal of study

Result

Reference

Iscador Qu

Recruiting
phase 3

To determine the
overall survival of
patients, evaluate the
quality of life, weight
of patients and to see
if the adverse effects
of
chemotherapy
decrease

---------

Wode,
2019

Iscucin
Populi,
Viscum Mali

Completed
phase 1

To determine the
safety of the
preparation

Both preparations
were found to be safe.

Huber et
al., 2011

Completed
phase 2

To determine the
maximum
dose,
safety,
and
effectiveness
of
viscum fraxini after
transurethral
resection
of
nonmuscle invasive
bladder cancer

Completed
phase 3

To determine the
quality
of
life,
immunomodulation,
and safety of adjuvant
mistletoe treatment in
patients with gastric
carcinoma receiving
chemotherapy after
operation

Abnoba
viscum
fraxini 2

Abnoba
viscum
quercus

There was no doselimiting toxicity up to
the administration of
675mg and 55.6% of
patients had complete
Rose et
remission
of
the al., 2015
marker tumour which
showed
strong
evidence
of
the
efficacy.
White blood cells
count, and eosinophils
increased, rate of
diarrhoea decreased,
Kim et al.,
increase in the quality
2012
of life of the patients
and the patient’s
global health status
increased

9. Final Remarks
It is apparent that mistletoe can be used to treat cancer as evident in the different pieces of
literature cited in this article. Pharmaceutical companies should investigate developing
mistletoe formulations as a treatment for cancer. There are several parameters that need to be
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considered, which include the type of mistletoe, the parts of mistletoe that are harvested, the
time and season of harvest and if the formulation is fermented or not. Pharmaceutical
processing and the season the mistletoe is harvested influences the concentration of chemical
substituents in mistletoe extracts (Urech & Baumgartner, 2015).
Mistletoe’s anti-cancer properties are due to a number of different pathways. Mistletoe can also
reduce the side effects and adverse drug reactions that are caused by chemotherapy and
radiotherapy (Marvibaigi et al., 2014). Therefore fewer drugs are required to treat the side
effects of the treatment and patients are also more likely to finish the medication as it is more
convenient to take one drug than two or three. Mistletoe can improve the patients’ healthrelated quality of life as it can reduce nausea and fatigue and reduce the hospitalization period
of the patient (Marvibaigi et al., 2014). These positive effects on the patient mean that the
patient is more likely to cooperate with treatment and achieving the desired outcome.
Mistletoe contains a number of constituents each of which target different pathways. The main
constituent that causes mistletoes anti-tumour and immunomodulatory effects is lectin
(Marvibaigi et al., 2014). Mistletoe lectin causes the excretion of cytokines and increases the
activity of NK cells (Marvibaigi et al., 2014). Viscotoxins have a cytotoxic effect. Viscotoxins
contain a phosphate-binding site. This binding site can interfere with a cell membrane and
destroy it (Zänker & Kaveri, 2015). Mistletoe lectin stimulates the patient’s immune system
and viscotoxins can cause tumour cell death. These constituents help the cancer patient to have
a better immune system which can help the patient avoid another illness which could have
affected the patient if their immune system is compromised with chemotherapy or radiotherapy.
Mistletoe formulations reduce the proliferation of cancer cells by a number of different
pathways which leads to the apoptosis of the cancer cells. The overproduction of PGE2 leads
to the promotion of cancer cell growth, migration, invasion, and survival (Greenhough et al.,
2009). Mistletoe preparations suppress COX-2 activities by posttranscriptional destabilizing of
its transcripts which stops the overproduction of PGE2 causing apoptosis (Oei et al., 2019).
Mistletoe also increases the activity of NK cells, which release a cytotoxic substance that
causes apoptosis (Iscador AG., 2018).

Further preclinical trials need to be undertaken in vitro to determine the anti-tumour activity of
the mistletoe preparation. More clinical trials should be conducted on mistletoe formulations
with a large number of participants to fully establish the safety and efficiency of the
formulation. The clinical trials should also find the standard dose for the preparation. These
trials should also take into account follow-up time to see the long-term effects, if any, of
mistletoe formulations (Marvibaigi et al., 2014).
Currently, there are two mistletoe clinical trials recruiting patients. The first one is a phase 3
clinical trial on Iscador Qu effect on the survival and HRQoL on pancreatic cancer patients
(Wode, 2019). The other trial is a phase 3 clinical trial on the efficacy of abnobaVISCUM 900
compared to mitomycin C monotherapy in patients with superficial bladder carcinoma by
evaluation of the time to tumour recurrence and a secondary objective to evaluate the safety of
abnobaVISCUM (Tschirdewahn, 2021). The mistletoe preparations Helixor M, and Iscador P
are currently undergoing active clinical trials that are not recruiting patients.
The cancers that mistletoe has been used to treat are breast, cervix, colon, ovary, stomach, and
lung cancers (Kaegi, 1998). In Ireland, lung, breast, ovary, and colon cancers are prevalent
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therefore mistletoe treatment would give patients another treatment option to consider when
deciding on a treatment plan.
Mistletoe has been proven safe and it has strong anti-cancer activity. Mistletoe formulation can
be used as an add-on treatment with chemotherapy and/or radiotherapy as it reduces side
effects. Pharmaceutical companies should consider producing an anti-cancer drug from
mistletoe.
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